Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Filings indexed 4,405 across all filing types
Latest filing 2025-10-27 Foreign Filer Report
Country FR France
Listing PA SAN

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-10-27 English
6-K
Foreign Filer Report
2025-10-24 English
6-K
Foreign Filer Report
2025-10-24 English
Communiqué de presse : T3 : croissance continue du chiffre d’affaires et du bénéfice
Earnings Release Classification · 100% confidence The document is a detailed quarterly financial press release from Sanofi for the third quarter (T3) of 2025. It contains comprehensive financial tables, analysis of revenue by segment and geography, business development updates, and management commentary on performance. It is not a short announcement (it is a full report of results) and provides detailed financial data, making it an Earnings Release (ER) which serves as the primary disclosure of quarterly financial results. Q3 2025
2025-10-24 French
Press release: Q3: continued sales and earnings progress
Earnings Release Classification · 100% confidence The document is a detailed quarterly financial results announcement from Sanofi, titled 'Q3: continued sales and earnings progress'. It contains key financial highlights, sales data by geography and product, pipeline updates, and management commentary. It is clearly an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q3 2025
2025-10-24 English
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsin
Regulatory Filings
2025-10-22 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.